Matteo Sarocchi, Junmin Li, Xiao Li, Depei Wu, Efreen Montaño Figueroa, Maria Guadalupe Rodriguez, Ming Hou, Carlo Finelli, Hong-Xia Shi, Zhijian Xiao, Esther Natalie Oliva, Liana Gercheva Kyuchukova, Mark Drummond, Argiris Symeonidis, Eric J Velazquez, Giulia Rivoli, Miguel Izquierdo, Yogita Kolekar, Paolo Spallarossa, Emanuele Angelucci
Iron overload from repeated transfusions has a negative impact on cardiac function, and iron chelation therapy may help prevent cardiac dysfunction in transfusion-dependent patients with myelodysplastic syndromes (MDS). TELESTO (NCT00940602) was a prospective, placebo-controlled, randomised study to evaluate the iron chelator deferasirox in patients with low- or intermediate-1-risk MDS and iron overload. Echocardiographic parameters were collected at screening and during treatment. Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failure (CHF) or worsening of cardiac function (HR = 0...
February 11, 2024: British Journal of Haematology